Clin Asst Prof Tan Jing Ying Tira

Dr. Tira J. Tan is a Senior Consultant Medical Oncologist at the National Cancer Centre Singapore (NCCS), specialising in breast cancer and early phase drug development.

She graduated with a BSc-MBBS from Imperial College London in 2006 and completed her postgraduate training in internal medicine in the UK and Singapore, earning MRCP (UK) in 2010 and specialist accreditation in medical oncology in 2015. Dr Tan further honed her expertise through a clinical fellowship at the Princess Margaret Cancer Centre in Toronto, Canada.

Dr Tan leads the Experimental Cancer Therapeutics Unit at NCCS and chairs the pre-operative and young women’s breast cancer programmes at NCCS. Her research focuses on novel therapeutics and treatment strategies for aggressive breast cancer subtypes, particularly triple-negative and luminal B cancers. She is a principal and co-investigator on multiple early and late phase clinical trials, including studies on immune-oncology and biomarker driven therapies.

An active educator, Dr Tan serves as Clinical Assistant Professor at Duke-NUS Medical school and is recognised for her mentorship and contributions to clinical research. Her works are supported by competitive grants from NMRC and Singapore Cancer Society, and she is committed to bridging laboratory discoveries with patient-centered cancer care.

• Bachelor of Science, Imperial College of Science & Technology, United Kingdom 
• Bachelor of Medicine, Bachelor of Surgery, Imperial College of Science & Technology, United Kingdom 
• MRCP (UK), Royal College of Physicians, United Kingdom 
• Specialist Certificate in Medical Oncology, Ministry of Health, Singapore

• Deputy Director, DMO Research, NCCS (2021-Current) 
• Deputy Director, Division of Clinical Trials and Epidemiology, NCCS 
• Clinical Assistant Professor, Duke-NUS Medical School 
• Clinical Lecturer, Yong Loo Lin School of Medicine (2014-Current) 
• Lead, Young Women’s Breast Cancer Program, NCCS (2020-Current) 
• Lead, Neoadjuvant Program, NCCS (2020-Current) 
• Member of American Society of Clinical Oncology 
• Member of European Society of Medical Oncology

• Master Clinical Trialist, Duke-NUS – 2024 
• Star Award – Singapore Health Quality Service Awards – 2022 
• 10 Years Long Service Award – 2019 
• Silver Award – Singapore Health Quality Service Awards – 2019

• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) 
• BAYER 21820: First-in-human dose-escalation and expansion study of the anti-CCR8 antibody BAY 3375968 in combination with pembrolizumab to evaluate the safety, tol-erability, and pharmacokinetics in participants with selected advanced solid tumors 
• TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Ra-tional For You (TAPISTRY) Phase II Platform Trial 
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) 
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer (HER2CLimb02)

• N Turner, C Saura, P Aftimos, E Tweel, M Oesterholt, N Koper, M Colleoni, E Kaczmarek, K Punie, X Song, A Armstrong, G Bianchi, A Stradella, S Ladoire, J Lim, N Quenel-Tueux, TJY Tan, S Escrivá-de-Romaní, J O'Shaughnessy, TULIP Trial Investigators. Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: an open label, randomized, phase III trial (TULIP)/ Journal of Clinical Oncology 2025; 43,5 (513-523).
• Horgan D, Tanner M, Aggarwal C, Thomas D, Grover S, Basel-Salmon L, Dienstmann R, Tan TJY, Park WY, Abu Rasheed HM, Siu LL, Ma B, Ortiz-López R, Van den Bulcke M, Taucher SC, Ferris A, Starling N, Malapelle U, Longshore J, Saldaña HAB, Subbiah V. Precision On-cology: A Global Perspective on Implementation and Policy Development. JCO Glob Oncol. 2025 Jan;11:e2400416. 
• Chan A, Chan D, Ng DQ, Zheng HF, Tan QM, Tan CJ, Toh JHM, Yap NY, Toh YL, Ke Y, Wang ECA, Lim QPN, Ho HK, Chew L, Tan TJ. HEalth-Related Quality of Life-Intervention in Survivors of Breast and Other Cancers Experiencing Cancer-Related Fatigue and Associated Cognitive Symptoms Using TraditionAL Chinese Medicine: The 'HERBAL' Trial. Integr Cancer Ther. 2025 Jan-Dec;24 
• Rahadian RE, Tan HQ, Ho BS, Kumaran A, Villanueva A, Sng J, Tan RSYC, Tan TJY, Tan VKM, Tan BKT, Lim GH, Cai Y, Nei WL, Wong FY. Using Machine Learning Models to Predict Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. JCO Clin Cancer Inform. 2024 Nov;8:e2400071. 
• J Z C Tan, J J Chan, R A Dent and T J Tan. (2024) Chapter 7 Early triple-negative breast cancer: systemic therapy. In F Cardoso, V Tjan-Heijnen, I Božović-Spasojević, M Vaz Batista (Ed.), Beast Cancer Essentials for Clinicians (pp. 41-46). ESMO Press. 
• TJY Tan, S Sammons, YH Im, L She, K Mundy, R Bigelow, T Traina, C Anders, J Yeong, E Renzulli, S Kim, RA Dent. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. Clinical Cancer Research. 1 Apr 2024; 30 (7), 1240-1247. 
• Spreafico A, Heirali AA, Araujo D, Tan TJY, Oliva M, Schneeberger P, Chen B, Wong M, Stayner LA, Hansen AR, Saibil SD, Wang B, Cochrane K, Sherriff K, Allen-Vercoe E, Xu W, Siu Lillian, Coburn B. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO Trial). An-nals of Oncology 2023; 34(6):520-530. 
• Yeong J, Goh D, Tan TJ, Tan B, Sivaraj H, Koh V, Tatt Lim JC, Joseph CR, Ye J, Yong Tay TK, Chan Lau M, Chan JY, Ng C, Iqbal J, Teh BT, Dent RA, Tan PH. Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression. Mod Pathol. 2023 Apr;36(4):100056. doi: 10.1016/j.modpat.2022.100056. Epub 2023 Jan 10. 
• TJY Tan, W Ang, W Whong, HS Chong, SH Tan, R Cheong, J Chia, N Syn, WH Shuen, R Ba, N Kaliaperumal, B Au, R Hopkins, X Li, A Tan, A Seet, J Connolly, T Arkachaisri, V Chew, A Lajam, D Guo, M Chew, M Wasser, P Kumar, Salvatore Albani, and Han Chong Toh. A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma. Nature Communications 2022; 13(1):6453-6453. 
• Tan TJ, Fink JL, Tay TK, Jaradi B, Stone N, Waring P, Koo KM, Tan PH, Tan DS, Dent RA. Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing? JCO Precis Oncol. 2022 Nov;6:e2200309. • Zhu G, Guo YA, Ho D, Poon P, Poh ZW, Wong PM, Gan A, Chang MM, Kleftogiannis D, Lau YT, Tay B, Lim WJ, Chua C, Tan TJY, Koo SL, Chong DQ, Yap YS, Tan I, Ng S, Skanderup AJ. Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden.Nature Communications 2021; 12(1):2229-2229 
• Loong HH, Shimizu T, Prawira A, Tan AC, Tran B, Day D, Tan DSP, Ting FIL, Chiu JW, Hui M, Wilson MK, Prasongsook N, Koyama T, Reungwetwattana T, Tan TJ, Heong V, Voon PJ, Park S, Tan IB, Chan SL, Tan DSW. Recommendations for the use of next-generation se-quencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group. ESMO Open. 2023 Aug;8(4):101586. doi: 10.1016/j.esmoop.2023.101586. Epub 2023 Jun 23. 
• Piha-Paul SA, Geva R, Tan TJ, Lim DW, Hierro C, Doi T, Rahma O, Lesokhin A, Luke JJ, Otero J, Nardi L, Singh A, Xyrafas A, Chen X, Mataraza J, Bedard PL. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combi-nation with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. J Immunother Cancer. 2021 Aug;9(8):e002863. 
• Seet AOL, Tan AC, Tan TJ, Ng MCH, Tai DWM, Lam JYC, Tan GS, Gogna A, Too CW, Tan BS, Takano A, Lim A, Lim TH, Lim ST, Dent RA, Ang MK, Yap YS, Tan IBH, Choo SP, Toh CK, Lim EH, Farid M, Skanderup AJ, Iyer NG, Lim WT, Tan EH, Lim TKH, Tan DSW. Individ-ualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience. JCO Precis Oncol. 2021 May 18;5:PO.20.00261. 
• Tira Tan and Rebecca Dent. (2018) Triple-Negative Breast Cancer: Clinical Features. In Tan Antoinette (Ed), Triple-Negative Breast Cancer A Clinician’s Guide). NY: Springer.
• T J Tan, J J Chan, R A Dent. Immunotherapy as Maintenance Treatment in Metastatic Triple Negative Breast Cancer. Journal of Cancer Metastasis and Treatment Mar 2021.